Drug facts

What to eat on tirzepatide

By David Chen·Editor·Reviewed September 2026

What the label says about food¹

Very little, and none of it is about what goes on the plate. The indication in section 1 reads: “ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity,” both to reduce excess body weight and keep it off, and to treat obstructive sleep apnea in adults with obesity. Section 2.4 repeats the pairing and adds the timing rule: once weekly, “at any time of day, with or without meals.”

The Medication Guide says the same in patient language: use it “with a reduced-calorie diet and increased physical activity,” and it “may be taken with or without food.”² That is everything the approved documents instruct about eating. They name the diet as part of the treatment without saying what it should contain.

An absence needs the list of what was read. This one covers the full text of the Zepbound prescribing information, the Medication Guide and the single-dose vial Instructions for Use, current in September 2026. None names a food, food group, meal pattern or drink to eat or to avoid.

What “reduced-calorie diet” meant in the trials³

Section 14.1 describes the lifestyle program behind the two main obesity trials, Study 1 and Study 2. Study 1, registered as NCT04184622, is SURMOUNT-1. In both, every participant received:

Diet

Instruction on a reduced-calorie diet, about 500 kcal a day below need.

Activity

Counseling toward more physical activity, a recommended minimum of 150 minutes a week.

Behavior

Counseling on behavior-change strategies to stick to the diet and exercise advice.

When

From the first dose of study drug or placebo, throughout the trial.

The placebo group got the same program with no drug, and that is what makes it useful to know about.⁴ In SURMOUNT-1, weight fell by 3.1% on placebo over 72 weeks and by 20.9% on the 15 mg dose. The diet and activity advice was the background to every weight figure the label reports, not an extra on top of the drug. What SURMOUNT-1 found →

The later trials used the same frame. Study 4, the withdrawal trial behind SURMOUNT-4, gave the same 500 kcal and 150-minute instruction from the first dose, and the sleep apnea trials in section 14.2 gave “instruction on a reduced-calorie diet and increased physical activity counseling” throughout.

The trial that put diet first³

Study 3 is the one place the label describes a stricter diet. Before anyone received the drug, participants spent 12 weeks on an intensive lifestyle program, delivered eight times by “a dietician or dietician-equivalent,” with instruction to reduce intake to about 1,200 kcal a day for women or 1,500 kcal for men and to exercise at least 150 minutes a week.

Only those who lost at least 5% of their weight on that program went on to be randomized: 579 of the 806 who enrolled. They had lost an average of 6.9% by diet and exercise alone. Over the next 72 weeks, back on the standard 500 kcal instruction, weight changed by a further 18.4% down on tirzepatide and 2.5% up on placebo. The label records it as a trial design, not as a recommendation to diet first.

Foods to avoid: the label names none⁵

No food, drink or ingredient is listed anywhere in the label as something to avoid, and no food is named as making a side effect better or worse. Lists of foods to avoid on tirzepatide circulate widely; none of them comes from the label, and this page does not publish one.

What the label does say about eating is what the drug does to it. Section 12.2 states that tirzepatide “decreases calorie intake” and that the effects “are likely mediated by affecting appetite,” and that it delays gastric emptying. Section 12.1 describes GLP-1 as “a physiological regulator of appetite and caloric intake.” How tirzepatide works → The label is equally silent on alcohol, which is covered in tirzepatide and alcohol.

Where the warnings touch eating⁶

Three of the label’s warnings bear on the stomach and on fluids. They are reported here as the label states them.

Anesthesia and sedation (5.9)

Rare postmarketing reports of pulmonary aspiration in people on GLP-1 receptor agonists who “had residual gastric contents despite reported adherence to preoperative fasting recommendations.” The label says the data are insufficient to say whether changing fasting instructions would help, and tells patients to inform providers before any planned procedure. Before surgery →

Severe gastrointestinal reactions (5.2)

The drug is not recommended in people with severe gastroparesis. The Medication Guide asks patients to tell their provider if they have “severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food.”

Dehydration and the kidneys (5.3)

Kidney injury was reported mostly in people dehydrated by nausea, vomiting or diarrhea. The Medication Guide’s one drinking instruction is here: “It is important for you to drink fluids to help reduce your chance of dehydration.” Diarrhea and dehydration →

Heartburn, reflux and indigestion are listed reactions with their own rates, set out in heartburn, reflux and burping. If the question behind the question is protein and muscle, what the trials measured is in muscle loss.

What none of this covers

Nothing here is medical or nutritional advice, and this page deliberately publishes no meal plan and no list of foods. A diet to go with this drug is the prescriber’s to set. See the medical disclaimer.